1380109-77-2

Upstream product

• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 15771-06-9 5-benzyloxy-2-hydroxymethyl-4H-pyran-4-one 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 

Downstream Products

• 1380110-29-1 C₄₃H₄₉N₉O₁₃S₂ 
• 1380110-32-6 2-((((Z)-2-(((2R,3S)-2-((3-((1,5-bis-(benzyloxy)-4-oxo-1,4-dihydropyridin-2-yl)methyl)ureido)-methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)-amino)oxy)-2-methylpropanoic acid tert-butyl ester 
• 1380110-33-7 (2R,3S)-2-((3-((1,5-bis(benzyloxy)-4-oxo-1,4-dihydropyridin-2-yl)methyl)ureido)methyl)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid 
• 1380110-39-3 tert-butyl ((2R,3S)-2-((3-((1,5-bis-(benzyloxy)-4-oxo-1,4-dihydropyridin-2-yl)methyl)ureido)-methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)-carbamate 
• 1380110-40-6 tert-butyl ((2R,3S)-2-((3-((1,5-bis-(benzyloxy)-4-oxo-1,4-dihydropyridin-2-yl)methyl)ureido)-methyl)-4-oxoazetidin-3-yl)carbamate 
• 1380110-42-8 1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)-methyl)-3-((1,5-bis(benzyloxy)-4-oxo-1,4-dihydropyridin-2-yl)methyl)urea trifluoroacetic acid salt 
• 1380110-56-4 C₄₂H₄₉N₇O₁₁S 
• 1380109-75-0 C₂₀H₁₇NO₄ 
• 1380109-76-1 C₂₁H₁₇NO₃ 
• 1380109-78-3 C₂₁H₂₁NO₆S 
• 1380109-79-4 C₂₈H₂₂N₂O₅ 
• 1380109-80-7 2-(aminomethyl)-1,5-bis(benzyloxy)-1,4-dihydropyridin-4-one 
• 1380110-97-3 C₄₈H₅₂N₈O₁₂S 
• 1380111-05-6 C₄₃H₅₁ClN₈O₁₁S 

Relevant academic research and scientific papers

New Pqs Quorum Sensing System Inhibitor as an Antibacterial Synergist against Multidrug-Resistant Pseudomonas aeruginosa

Development of new bacterial biofilm inhibitors as antibacterial synergists is an effective strategy to solve the resistance of Pseudomonas aeruginosa. In this paper, a series of 3-hydroxy-pyridin-4(1H)-ones were synthesized and evaluated, and the hit compound (20p) was identified with the effects of inhibiting the production of pyocyanin (IC50 = 8.6 μM) and biofilm formation (IC50 = 4.5 μM). Mechanistic studies confirmed that 20p inhibits the formation of bacterial biofilm by inhibiting the expression of pqsA, blocking pqs quorum sensing system quinolone biosynthesis. Moreover, we systematically investigated the bactericidal effects of combining currently approved antibiotics for CF including tobramycin, ciprofloxacin, and colistin E with 20p, which showed obvious antibacterial synergy to overcome antibiotics resistance in multidrug-resistant P. aeruginosa biofilms. The result indicates that compound 20p may be used in the future as a potentially novel antibacterial synergist candidate for the treatment of P. aeruginosa infections.

Pyridone-conjugated monobactam antibiotics with gram-negative activity

Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monobactam analogues with in vitro antibacterial activity against clinically relevant Gram-negative species including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Rat pharmacokinetic studies with compound 17 demonstrate low clearance and low plasma protein binding. In addition, evidence is provided for a number of analogues suggesting that the siderophore receptors PiuA and PirA play a role in drug uptake in P. aeruginosa strain PAO1.

MONOBACTAMS

The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.